New Monoclonal Antibody Prevents RSV in Infants and Toddlers
- Diane Aschenbrenner
Access Resources
About
This article discusses the approval of the monoclonal antibody nirsevimab-alip (Beyfortus) to prevent respiratory syncytial virus (RSV) in high-risk neonates and infants up to 24 months old. It emphasizes that this antibody, given via injection at the start of the RSV season, helps reduce the risk of severe RSV symptoms. The safety and effectiveness of nirsevimab-alip were supported by three clinical trials, showing a decrease in medically attended RSV lower respiratory tract infections. However, caution is advised due to potential serious hypersensitivity reactions. This development is significant for vulnerable children at risk of severe RSV disease.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.